Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDA2
NCT03244241Phase 4Unknown
- Start
- Apr 2017
- Primary completion
- Apr 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin degludec in type 2 diabetes mellitus (T2DM) (2 arms). Primary endpoint: Difference in mean daily plasma glucose between the two groups at 8 days. Status: unknown.
02
Drugs
insulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03244241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03244241.